两种内脏痛觉过敏大鼠模型痛觉效能的比较

目的比较两种内脏痛觉过敏大鼠模型的痛觉特点和有效性,为实验提供模型选择依据。方法SD大鼠分别给予单纯结肠直肠扩张和炎症刺激后结肠直肠扩张,通过腹部撤退反射和腹外斜肌放电监测大鼠痛觉敏化程度。结果两种大鼠模型都能复制出明确的行为学改变,脊髓相应节段Fos蛋白表达明显。炎症刺激后结肠直肠扩张大鼠痛行为出现明显且稳定,单纯结肠直肠扩张刺激痛行为时间一致性好。结肠直肠扩张压力为15～60mmHg时,腹外斜肌放电有明显改变,而腹壁撤退反射只在15～45mmHg压力范围内有改变。结论在探讨消化系统疾病、痛觉机制或药物效果评价时,应根据模型特点和实验需要进行选择。     

反复电针对慢性痛的累加治疗作用及其机制研究

本研究从基础和临床两方面观察了反复电针对慢性痛的累加治疗作用,并结合疼痛患者及慢性痛动物模型中几种神经肽的放射免疫测定及相应受体拮抗剂的药理学研究结果,探讨了产生累加效应的可能机制。结果表明,在临床脊髓损伤性痉挛患者,１００Ｈｚ穴位体表电刺激有效地缓解痉挛并有累加效应;在临床慢性痛患者,２／１５Ｈｚ变频ＴＥＮＳ刺激有效地治疗疼痛并具有累加效应。在关节炎模型大鼠,电针刺激能产生明显的镇痛并具有累加效     

斑马鱼作为骨骼疾病模型的研究进展

斑马鱼作为一种优良的动物模型已被广泛应用于人类相关疾病机理及药物筛选的研究。由于斑马鱼骨骼发育过程和调控机制与哺乳动物高度保守,目前已成功构建斑马鱼骨骼疾病模型。本文首先介绍斑马鱼骨骼发育过程和分子调控机制,并对斑马鱼模型骨骼研究的基本方法及在骨骼药物筛选中的研究现状进行分析和总结,以期对斑马鱼作为骨骼疾病模型进行药物筛选或基础研究提供参考。     

福尔马林引起的急性内脏炎症痛模型

目的：为深入开展内脏痛的研究,建立急性内脏炎症痛模型。方法：实验选用Ｗｉｓｔａｒ 大鼠,雌雄不拘,体重２４０～２７０ ｇ。本实验分两个部分：①大鼠乙状结肠壁粘膜下注射福尔马林（０ ．１ｍｌ,５ ％） 复制急性内脏炎症痛模型;②检测吗啡（１ ｍｇ／ｋｇ,２ ｍｇ／ｋｇ,４ ｍｇ／ｋｇ）对模型疼痛分数的影响。结果：①福尔马林具有显著的致痛效应,实验组的疼痛分数显著高于对照组（ Ｐ＜ ０．０１） ;②疼痛分数能够反映内脏疼痛程度;③吗啡对模型具有显著、剂量依赖的止痛效应（Ｐ＜ ０．０１） 。结论：①大鼠乙状结肠壁粘膜下注射福尔马林可作为急性内脏炎症痛模型;②疼痛分数能客观反映了内脏疼痛程度,可作为量化指标     

胞内记录猫体感皮层内脏伤害性感受神经元的电生理特性

为了从细胞水平探讨皮层内脏伤害感受的特性及机制,本文应用细胞内电位记录技术,观察了猫体感皮层内脏大神经皮层代表区的８５１个神经元对电刺激内脏大神经的诱发反应及电生理特性。其中４１２个单位为内脏伤害性感受神经元,其自发放电有多种形式,根据诱发反应现象分为特异性和非特异性伤害感受神经元,内脏伤害性诱发反应分为兴奋性反应（５１７％）、抑制性反应（３１３１％）及混合性反应（１７％）三类。在形式上具有潜伏期长、反应形式复杂等特点。实验发现８５个神经元为内脏及肋间神经的会聚反应细胞。部分神经元用神经生物素进行细胞内电泳标记以显示功能细胞所在层次及形态。结果说明皮层体感神经元具有内脏伤害性感受的作用,并从细胞及突触后电反应特点上探讨了内脏痛的感受机制。     

一种刺激内脏大神经的慢性测痛方法

用聚四氟乙烯绝缘多股银丝作双极电极,埋置于左侧大内脏神经上,以刺激大内脏神经引起行为反应所需的最小电流强度作为内脏痛觉阈值。刺激参数为短串单相方波,串长500ms,波宽1ms,频率40Hz,强度为每隔5s递增约0.1mA,至出现行为反应时停止。30只家兔121次测试,内脏痛阈均值为1.16±0.056mA。在18只家兔中每只兔测定12次痛阈,其阈值相当稳定,波动在0.07mA 之间,用随机区组方差分析无显著意义。在14只家兔中静脉注射芬坦尼(20μg/kg),5min 后阈值升高显著,维持15min,其后渐趋恢复。作者认为,本方法可用于测定内脏痛阈的实验研究。     

慢性应激致肠易激综合征大鼠模型的建立与评价

目的建立一种模拟肠易激综合征临床症状的动物模型,为相关药物的研究提供实验基础。方法采用孤养附加慢性不可预见性刺激建立IBS模型,每只大鼠受到的刺激因子包括:24h禁水、24h禁食、昼夜颠倒、4℃冰水游泳15min、45℃高温5min、钳尾致痛1min、束缚制动5～8h、高速震荡15min等共8种,每种刺激因子出现5次,共40d。用腹部回撤反射压力阈值(AWR)和排便粒数检测动物的内脏感觉和胃肠运动功能变化;用敞箱行为评分和蔗糖水偏嗜度评价动物神经精神活动变化。结果造模2～3周腹部回撤反射压力阈值明显降低,排便粒数明显增加;造模3～4周模型组动物敞箱实验行为评分和蔗糖水偏嗜度明显降低。造模40d时,上述变化趋势仍存在。结论慢性应激加孤养可诱导动物胃肠运动亢进、内脏感觉致敏和神经精神活动的改变,模拟IBS患者的临床特征,可作为一种有效的IBS动物模型,用于评价相关药物。     

癌症痛的神经生物学机制研究进展

癌症痛是影响癌症病人生活质量的一个严重问题 ,但长期以来由于缺乏合适的动物模型 ,对其神经机制的研究甚少。近年出现的小鼠股骨、跟骨、肱骨和大鼠胫骨癌症痛模型 ,极大地推动了癌症痛的基础研究。初步研究表明 ,癌症痛有其独特的神经化学机制 ,骨质破坏、外周敏化、中枢敏化及神经侵蚀都参与了癌症痛的产生。本文综述了癌症痛动物模型、癌症痛的产生机制及其药物治疗等方面的研究进展。     

癌痛的分子机理研究进展

疼痛是肿瘤患者的常见并发症。癌痛的产生不同于炎性痛和神经病理性疼痛。动物模型的构建能帮助我们更好地了解癌痛的分子调控机制。随着对癌痛机制的进一步研究,未来针对性的靶点镇痛治疗指日可待。本文就研究癌痛的动物模型及癌痛产生的相关分子机制等方面的进展进行综述。     

兔隔核刺激及隔核阿片受体在镇内脏痛中的作用

本工作以电刺激内脏大神经测定清醒家兔的内脏痛阈。实验观察到,以弱电流刺激隔核对内脏痛阈有升高、降低和无明显变化三种效应;向家兔双侧隔核注入阿片受体激动剂埃托啡(etorphine)2μg/2μl,注药后 5min,内脏痛阈即升高,维持 40min;静脉注射纳洛酮O.2mg/kg或 2μg/2μl纳洛酮注入中脑导水管周围灰质(PAG)均能阻断隔核内注入埃托啡的镇痛作用;电针刺激能抑制内脏痛,静脉注射纳洛酮 0.4mg/kg 能阻断这一效应,但对电针后效应无明显影响,向隔核内注入纳洛酮 2μg/2μl亦能阻断针效,而且后效应消失。结果提示,镇内脏痛与内阿片肽活动有关,隔核的阿片受体被激活即有明显抑制内脏痛的作用,其作用的传出通路可能通过 PAG;隔核的阿片受体参与电针镇内脏痛过程。     

扣带回前部内脏伤害感受神经元的生物电活动

为了从神经元水平探讨大脑皮层内脏伤害感受的特性及机制,应用玻璃微电极细胞内电位记录技术,研究18只猫扣带回前部312个神经元的自发生物电活动,及其对电刺激同侧内脏大神经的诱发反应.其中,82个为内脏伤害感受神经元,其自发生物电活动有5种主要形式.根据诱发反应的潜伏期等特性,内脏伤害感受神经元分为特异性内脏伤害感受神经元（76个,92.68％）和非特异性内脏伤害感受神经元（6个,7.32％）.内脏伤害性诱发反应分为兴奋性（65.86％）、抑制性（17.07％）及混合性反应（17.07％）3种.结果提示内脏大神经的传入通路投射到同侧扣带回前部;扣带回前部神经元具有内脏伤害感受作用,存有特异性与非特异性内脏伤害感受神经元,为痛觉特异性学说提供了新的实验依据.     

A Mouse Model for Pathogen-induced Chronic Inflammation at Local and Systemic Sites

Chronic inflammation is a major driver of pathological tissue damage and a unifying characteristic of many chronic diseases in humans including neoplastic, autoimmune, and chronic inflammatory diseases. Emerging evidence implicates pathogen-induced chronic inflammation in the development and progression of chronic diseases with a wide variety of clinical manifestations. Due to the complex and multifactorial etiology of chronic disease, designing experiments for proof of causality and the establishment of mechanistic links is nearly impossible in humans. An advantage of using animal models is that both genetic and environmental factors that may influence the course of a particular disease can be controlled. Thus, designing relevant animal models of infection represents a key step in identifying host and pathogen specific mechanisms that contribute to chronic inflammation.Here we describe a mouse model of pathogen-induced chronic inflammation at local and systemic sites following infection with the oral pathogen Porphyromonas gingivalis, a bacterium closely associated with human periodontal disease. Oral infection of specific-pathogen free mice induces a local inflammatory response resulting in destruction of tooth supporting alveolar bone, a hallmark of periodontal disease. In an established mouse model of atherosclerosis, infection with P. gingivalis accelerates inflammatory plaque deposition within the aortic sinus and innominate artery, accompanied by activation of the vascular endothelium, an increased immune cell infiltrate, and elevated expression of inflammatory mediators within lesions. We detail methodologies for the assessment of inflammation at local and systemic sites. The use of transgenic mice and defined bacterial mutants makes this model particularly suitable for identifying both host and microbial factors involved in the initiation, progression, and outcome of disease. Additionally, the model can be used to screen for novel therapeutic strategies, including vaccination and pharmacological intervention.     

Two-dimensional predictive equation to classify visceral obesity in clinical practice

Objective: Visceral obesity assessment is not easy, and although computed tomography (CT) is an accurate tool, this technique is expensive and sometimes not suitable in clinical practice. We developed a new two‐dimensional elliptical anthropometric equation to classify visceral obesity and evaluated the validity and the reliability of the new equation compared with CT. Research Methods and Procedures: We collected anthropometric and CT data from overweight/obese subjects (n = 61, BMI = 32.4 ± 3.7 kg/m²). A validation group of 32 subjects was also selected. An equation for the assessment of visceral obesity was developed using multiple regression analysis. Once validated, the equation was compared with previous models. Tests for accuracy included mean differences, analysis of diagnostic, R², Snedecor's F‐test, and Bland‐Altman plot. Results: Multiple regression analysis revealed that the sagittal and coronal diameters and the triceps skinfold were significant contributors to the model. The final equation was: visceral area (VA)/subcutaneous area (SA)_predicted = 0.868 + 0.064 × sagittal diameter ?0.036 × coronal diameter ?0.022 × triceps skinfold. Patients with visceral‐subcutaneous area ratio (VA/SA) >0.42 were classified as having visceral obesity. The predictive equation was valid, showing a significant association with VA/SA assessed by CT (VA/SA_CT; r = 0.68; p < 0.0001). Paired Student's t test showed no significant differences with VA/SA_CT (p = 0.541). The reliability was high [F(24/60) = 2.12; p = 0.01]. Discussion: The new two‐dimensional and elliptical predictive equation is valid to assess visceral obesity and is more precise than previous models.     

The role of TRPA1 in visceral inflammation and pain

Despite significant progress in our understanding of the cellular and molecular mechanisms underlying sensory transduction and nociception, clinical pain management remains a considerable challenge in health care and basic research. The identification of the superfamily of transient receptor potential (TRP) cation channels, particularly TRPV1 and TRPA1, has shed light on the molecular basis of pain signaling during inflammatory conditions. TRPV1 and TRPA1 are considered as potential targets in the treatment of inflammatory pain because of their ability to be activated by nociceptive signals and sensitized by pro-inflammatory mediators. Notably, TRPA1 is expressed in visceral afferent neurons and is known to participate in inflammatory responses and the establishment of hypersensitivity. This review summarizes the current knowledge of the role of TRPA1 in sensory transduction, particularly in the context of visceral inflammation and pain in the gastrointestinal and urinary tracts.     

The role of TRPA1 in visceral inflammation and pain

Despite significant progress in our understanding of the cellular and molecular mechanisms underlying sensory transduction and nociception, clinical pain management remains a considerable challenge in health care and basic research. The identification of the superfamily of transient receptor potential (TRP) cation channels, particularly TRPV1 and TRPA1, has shed light on the molecular basis of pain signaling during inflammatory conditions. TRPV1 and TRPA1 are considered as potential targets in the treatment of inflammatory pain because of their ability to be activated by nociceptive signals and sensitized by pro-inflammatory mediators. Notably, TRPA1 is expressed in visceral afferent neurons and is known to participate in inflammatory responses and the establishment of hypersensitivity. This review summarizes the current knowledge of the role of TRPA1 in sensory transduction, particularly in the context of visceral inflammation and pain in the gastrointestinal and urinary tracts.     

Role of neurogenic inflammation in pancreatitis and pancreatic pain

Pain arising from pancreatic diseases can become chronic and difficult to treat. There is a paucity of knowledge regarding the mechanisms that sensitize neural pathways that transmit noxious information from visceral organs. In this review, neurogenic inflammation is presented as a possible amplifier of the noxious signal from peripheral organs including the pancreas. The nerve pathways that transmit pancreatic pain are also reviewed as a conduit of the amplified signals. It is likely that components of these visceral pain pathways can also be sensitized after neurogenic inflammation.     

Comparison of body fat composition and serum adiponectin levels in diabetic obesity and non-diabetic obesity

Objective: Clinical aspects of diabetes and obesity are somewhat different, even at similar levels of insulin resistance. The purpose of this study was to determine differences in body fat distribution and serum adiponectin concentrations in diabetic and non‐diabetic obese participants. We were also interested in identifying the characteristics of insulin resistance in these two groups, particularly from the standpoint of adiponectin. Research Methods and Procedures: Adiponectin concentrations of 112 type 2 diabetic obese participants and 124 non‐diabetic obese participants were determined. Abdominal adipose tissue areas and midthigh skeletal muscle areas were measured by computed tomography. A homeostasis model assessment of the insulin resistance score was calculated to assess insulin sensitivity. The relationships among serum adiponectin, body fat distribution, and clinical characteristics were also analyzed. Results: Both abdominal subcutaneous and visceral fat areas were higher in the non‐diabetic obese group, whereas midthigh low‐density muscle area was higher in the diabetic obese group. The homeostasis model assessment of the insulin resistance score was similar between groups, whereas serum adiponectin was lower in the diabetic obese group. Abdominal visceral fat (β = ?0.381, p = 0.012) was a more important predictor of adiponectin concentration than low‐density muscle (β = ?0.218, p = 0.026) in cases of non‐diabetic obesity, whereas low‐density muscle (β = ?0.413, p = 0.013) was a better predictor of adiponectin level than abdominal visceral fat (β = ? 0.228, p = 0.044) in diabetic obese patients. Discussion: Therefore, factors involved in pathophysiology, including different serum adiponectin levels and body fat distributions, are believed to be responsible for differences in clinical characteristics, even at similar levels of insulin resistance in both diseases.     

心肺复苏后脑缺血再灌注损伤治疗理念及相关动物模型研究进展

心肺复苏后脑缺血再灌注损伤是一个复杂的病理生理变化过程,由多种损伤机制共同参与。自心肺复苏后系统性综合治疗和亚低温治疗在临床上广泛应用后,目前已有多种治疗理念在不同的动物实验和动物模型基础上被提出,包括缺血预处理、药物预处理、缺血后处理、和药物后处理,而后吸入麻醉药对心肺复苏后脑缺血再灌注损伤的保护作用受到了人们的重视,而七氟烷后处理已经成为目前研究的热点之一。为了指导临床上的心肺复苏,人们一直在利用不同动物模型,探究不同保护方法,寻找有效的脑保护药物。而各种治疗理念的提出均是建立在动物实验和动物模型的基础上,窒息性心肺复苏模型模拟围术期气道梗阻,能较贴切的复制临床上由窒息引起的心肺复苏后脑损伤,对将来指导临床复苏具有重大意义。     

Markedly attenuated acute and chronic pain responses in mice lacking adenylyl cyclase-5

Chronic inflammatory and neuropathic pain is often difficult to manage using conventional remedies. The underlying mechanisms and therapeutic strategies required for the management of chronic pain need to be urgently established. The cyclic AMP (cAMP) second messenger system has been implicated in the mechanism of nociception, and the inhibition of the cAMP pathway by blocking the activities of adenylyl cyclase (AC) and protein kinase A has been found to prevent chronic pain in animal models. However, little is known regarding which of the 10 known isoforms of AC are involved in nociceptive pathways. Therefore, we investigated the potential pronociceptive function of AC5 in nociception using recently developed AC5 knockout mice (AC5-/-). We found that AC5-/- mice show markedly attenuated pain-like responses in acute thermal and mechanical pain tests as compared with the wildtype control. Also, AC5-/- mice display hypoalgesic responses to inflammatory pain induced by subcutaneous formalin injection into hindpaws, and to non-inflammatory and inflammatory visceral pain induced by injecting magnesium sulfate or acetic acid into the abdomen. Moreover, AC5-/- mice show strongly suppressed mechanical and thermal allodynia in two nerve injury-induced neuropathic pain models. These results suggest that AC5 is essential for acute and chronic pain, and that AC5 knockout mice provide a useful model for the evaluation of the pathophysiological mechanisms of pain.     

Murine models of human neuropathic pain

Neuropathic pain refers to pain that originates from pathology of the nervous system. Diabetes, infection (herpes zoster), nerve compression, nerve trauma, and autoimmune diseases are examples of diseases that may cause neuropathic pain. Unfortunately no satisfactory treatment is yet available for this type of pain. This consideration has led to an explosion of interest for the underlying mechanisms, accompanied by a growing number of animal models. In recent years, most of the neuropathic pain models initially developed in the rat have been translated to mice in order to exploit the resource represented by genetically modified mice. Obviously the most useful animal models of pain would be ones in which the etiology of the pain would be endogenous and not induced by the experimenters: together with the classic models based on peripheral nerve ligation, in the last years other techniques are being developed that mimic more closely clinical pain syndromes, often by attempting to induce the disease associated to neuropathic pain. Although several variables must be taken into account when using animal models for mimicking clinical neuropathic pain, the huge number of models that are now reproducible and well characterized should help to reach important goals in the comprehension of mechanisms and to discover novel therapeutic target for this disease.